作者: Andrew V Schally , Xianyang Zhang , Renzhi Cai , Joshua M Hare , Riccarda Granata
关键词: Receptor 、 Internal medicine 、 Medicine 、 Downregulation and upregulation 、 In vivo 、 Neuroprotection 、 Transplantation 、 Growth hormone–releasing hormone 、 Immune system 、 Growth factor 、 Endocrinology
摘要: In this article, we briefly review the identification of GHRH, provide an abridged overview GHRH antagonists, and focus on studies with agonists. Potent agonists JI MR class were synthesized evaluated biologically. Besides induction release pituitary GH, analogs promote cell proliferation exert stimulatory effects various tissues, which express receptors (GHRH-Rs). A large body work shows that agonists, such as MR-409, improve pancreatic β-cell metabolic functions facilitate engraftment islets after transplantation in rodents. Accordingly, offer a new therapeutic approach to treating diabetes. Various demonstrate repair cardiac tissue, producing improvement ejection fraction reduction infarct size rats, scar swine, attenuation hypertrophy mice, suggesting clinical applications. The presence GHRH-Rs ocular tissues neuroprotective experimental diabetic retinopathy indicates their possible applications for eye diseases. Other include acceleration wound healing, activation immune cells, action central nervous system. As might function growth factor, examined tumors. vitro, stimulate human cancer cells upregulate GHRH-Rs. However, vivo, inhibit cancers xenografted into nude mice downregulate tumoral Therapeutic are discussed. development should lead use.